EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

5. Does a patient-specific prescription make compounded semaglutide permissible?

Dose Diligence research deskSection 01 · Page 5 of 34Last updated 17 Nov 2026

No. A prescription bearing a patient’s name is not, by itself, a sufficient significant-difference determination under FDA’s 503A copying guidance. The guidance describes a change producing a significant difference for the identified patient, as determined by the prescriber, and recommends documenting that determination. (fda.gov)

Ask the medical director and counsel to review:

  1. The approved comparator.
  2. The actual formulation change.
  3. The patient-specific reason for that change.
  4. The prescriber’s independent determination.
  5. How the pharmacy receives and retains the documentation.
  6. Whether the other applicable compounding conditions are satisfied.

Do not ask procurement staff to generate clinical justifications, and do not treat a supplier’s pre-filled rationale as evidence of an independent prescribing decision.

FDA’s guidance also states that lower price does not establish the required formulation-related difference. Affordability should be addressed through the access comparison, not presented as an automatic copying exception. (fda.gov)

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
Section sources →